pms-601 and Cognition-Disorders

The neuroregulatory activities of PMS-601, a platelet activating factor antagonist, were investigated in laboratory and animal models of HIV-1 encephalitis (HIVE). For the former, PMS-601 reduced monocyte-derived macrophage pro-inflammatory secretions, multinucleated giant cell (MGC) formation, and neuronal loss independent of antiretroviral responses. PMS-601 treatment of HIVE severe combined immunodeficient mice showed reduced microgliosis, MGCs and neurodegeneration. These observations support the further development of PMS-601 as an adjunctive therapy for HIV-1 associated neurocognitive disorders.

Topics: AIDS Dementia Complex; Animals; Anti-Inflammatory Agents; Brain; Cell Death; Cells, Cultured; Cognition Disorders; Disease Models, Animal; Focal Adhesion Kinase 2; Giant Cells; Gliosis; Humans; Immunologic Factors; Inflammation Mediators; Male; Mice; Mice, SCID; Microglia; Monocytes; NF-kappa B; Piperazines; Platelet Activating Factor